Evgen Pharma PLC Posting of Circular & Notice of GM (8624O)
February 12 2021 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 8624O
Evgen Pharma PLC
12 February 2021
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Posting of Circular
and
Notice of General Meeting
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company, announces that further to its announcement of the proposed
Fundraising on 2 February 2021 (the " Placing Announcement "), a
Circular, including the notice of General Meeting, a Form of Proxy
and (where applicable) an Open Offer Application Form are today
being posted to shareholders. The General Meeting will be held at
10:00 a.m. on 3 March 2021.
In light of the current restrictions in place with respect to
the COVID-19 pandemic and, in particular, the UK Government's
response (including guidance on working from home in place at the
date of this notice), the Company's Board of Directors have
concluded that the General Meeting will be held as a closed
meeting. The Company will make arrangements such that the legal
requirements to hold the General Meeting can be satisfied through
the electronic attendance of the minimum number of shareholders,
drawn from members of the Board. No other shareholder will be able
to attend the General Meeting and are, instead, requested to
complete the Form of Proxy, appointing the chairman of the meeting,
rather than a third party, as their proxy by the relevant time.
Copies of the Circular and Form of Proxy will be made available
on the Company's website www.evgen.com .
Capitalised terms used in this announcement shall have the same
meanings as the definitions in the Placing
Announcement unless otherwise defined herein .
Enquiries:
Evgen Pharma plc Via Walbrook
Barry Clare, Chairman
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane / Sunila de Silva
(ECM)
www.finncap.com +44 (0) 20 7220 0500
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
Paul McManus/ Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876
741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOGTBMFTMTJBBPB
(END) Dow Jones Newswires
February 12, 2021 02:00 ET (07:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024